- Home
- ONFO vs THAR Comparison
ONFO vs THAR Comparison
Compare ONFO & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- THAR
- Stock Information
- Founded
- ONFO 2018
- THAR 2017
- Country
- ONFO United States
- THAR United States
- Employees
- ONFO N/A
- THAR N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- THAR Health Care
- Exchange
- ONFO Nasdaq
- THAR Nasdaq
- Market Cap
- ONFO 5.4M
- THAR 5.5M
- IPO Year
- ONFO 2022
- THAR 2022
- Fundamental
- Price
- ONFO $1.04
- THAR $1.35
- Analyst Decision
- ONFO
- THAR Strong Buy
- Analyst Count
- ONFO 0
- THAR 1
- Target Price
- ONFO N/A
- THAR $17.00
- AVG Volume (30 Days)
- ONFO 57.3K
- THAR 119.3K
- Earning Date
- ONFO 08-14-2025
- THAR 08-14-2025
- Dividend Yield
- ONFO N/A
- THAR N/A
- EPS Growth
- ONFO N/A
- THAR N/A
- EPS
- ONFO N/A
- THAR N/A
- Revenue
- ONFO $10,508,728.00
- THAR N/A
- Revenue This Year
- ONFO N/A
- THAR N/A
- Revenue Next Year
- ONFO N/A
- THAR N/A
- P/E Ratio
- ONFO N/A
- THAR N/A
- Revenue Growth
- ONFO 78.36
- THAR N/A
- 52 Week Low
- ONFO $0.61
- THAR $0.95
- 52 Week High
- ONFO $1.88
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- ONFO 45.84
- THAR 46.35
- Support Level
- ONFO $0.94
- THAR $1.15
- Resistance Level
- ONFO $1.26
- THAR $1.66
- Average True Range (ATR)
- ONFO 0.11
- THAR 0.12
- MACD
- ONFO -0.02
- THAR 0.01
- Stochastic Oscillator
- ONFO 27.75
- THAR 39.22
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.